Akero - Rasio total nilai perusahaan marang pendapatan AKRO

Logo perusahaan publik Akero (AKRO)

Akero Therapeutics (AKRO) profitability is based on the commercialization of the EFX drug against NASH fibrosis. The price-to-sales ratio illustrates the business valuation dynamics, where 0.00 serves as the current parameter value. Progress in treating metabolic disorders is achieved through partnerships with clinics, while development flexibility is ensured by outsourcing tests to external laboratories.

AKRO Akero Therapeutics: Rasio nilai perusahaan marang pendapatan ing interval 23.11.2025 - 20.12.2025

AKRO (Akero Therapeutics, Inc.): rincian analitis lan laporan miturut indikator

- rega saham lan prakiraan rega para ahli:
- informasi babagan dhuwit lan arus kas:
Pambiji fundamental perusahaan:AKRO, akerotx.com
Produk seri Akero

The prospects for Akero Therapeutics (AKRO) depend on the outcome of efruxifermin clinical trials and a potential acquisition by a pharma behemoth in the MASH therapy segment. The firm's valuation via the EV/Sales multiple relates the total enterprise value to revenue regardless of debt load, allowing investors to determine the premium paid for future growth rates or identify an undervalued asset by analyzing the price action on this chart.

Analisis pesaing

ASND: Rasio nilai perusahaan marang pendapatan|MDGL: Multiplikator EV/Sales|CORT - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Rhythm Corp|Metsera Therapeutics (MTSR) - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan moonlaketx.com (MLTX)|Nilai perusahaan marang pendapatan Crinetics Pharmaceuticals CRNX|Rasio nilai perusahaan marang pendapatan NewAmsterdam Pharma N.V. NAMS|Rasio total nilai perusahaan marang pendapatan Soleno Therapeutics Inc (SLNO)|FOLD - Rasio nilai perusahaan marang pendapatan|ETNB: Rasio nilai perusahaan marang pendapatan|AGIO: Multiplikator EV/Sales|Structure Therapeutics Inc. - Nilai bisnis marang pendapatan|MDXG (MiMedx Corp) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Rezolute Inc RZLT|Multiplikator EV/Sales LXRX|Rasio total nilai perusahaan marang pendapatan MBX Corp|Altimmune Pharma - Nilai perusahaan marang pendapatan|Multiplikator EV/Sales aardvarktherapeutics.com AARD|SGMT: Nilai perusahaan marang pendapatan|Nilai bisnis marang pendapatan BIOA (BioAge Labs)|BMEA: Multiplikator EV/Sales|QNCX: Koefisien nilai perusahaan marang pendapatan|GUTS (Fractyl Health, Inc.) - Multiplikator EV/Sales|Multiplikator EV/Sales vtvtherapeutics.com|Nilai perusahaan marang pendapatan ATPC (Agape ATP Corp)|Rasio total nilai perusahaan marang pendapatan Pluristem Therapeutics|Rasio nilai perusahaan marang pendapatan synlogictx.com SYBX|LPCN: Rasio nilai perusahaan marang pendapatan|MTNB - Rasio nilai perusahaan marang pendapatan|Spruce Biosciences, Inc. (SPRB) - Nilai perusahaan marang pendapatan|GLTO: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - Multiplikator EV/Sales|Organovo Corp (ONVO) - Rasio total nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan Radius Recycling (RDUS)